Phillip Schwartz - Jan 20, 2022 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role: President of R&D, Director
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-fact
Stock symbol: ENTX
Transactions as of: Jan 20, 2022
Transactions value $: $25,250
Form type: 4
Date filed: 1/24/2022, 03:17 PM
Previous filing: Jan 11, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Purchase	$25.3K	+10K	+1.67%	$2.53	607K	Jan 20, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.49 to $2.56, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.49 to $2.56, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.